Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

SNDL vs CGC vs CRON vs ACB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SNDL
SNDL Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$376M
5Y Perf.-83.0%
CGC
Canopy Growth Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$122M
5Y Perf.-99.3%
CRON
Cronos Group Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$981M
5Y Perf.-60.6%
ACB
Aurora Cannabis Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$195M
5Y Perf.-97.6%

SNDL vs CGC vs CRON vs ACB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SNDL logoSNDL
CGC logoCGC
CRON logoCRON
ACB logoACB
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$376M$122M$981M$195M
Revenue (TTM)$937M$294M$193M$361M
Net Income (TTM)$-11M$-327M$-9M$41M
Gross Margin27.2%22.8%32.5%62.7%
Operating Margin-0.8%-24.1%-1.5%13.3%
Forward P/E34.3x164.2x
Total Debt$170M$348M$2M$104M
Cash & Equiv.$273M$114M$792M$184M

SNDL vs CGC vs CRON vs ACBLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SNDL
CGC
CRON
ACB
StockMay 20May 26Return
SNDL Inc. (SNDL)10017.0-83.0%
Canopy Growth Corpo… (CGC)1000.7-99.3%
Cronos Group Inc. (CRON)10039.4-60.6%
Aurora Cannabis Inc. (ACB)1002.4-97.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: SNDL vs CGC vs CRON vs ACB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CRON leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Aurora Cannabis Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
SNDL
SNDL Inc.
The Specific-Use Pick

SNDL plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
CGC
Canopy Growth Corporation
The Secondary Option

CGC lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
CRON
Cronos Group Inc.
The Income Pick

CRON carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.

  • beta 0.98
  • 14.6% 10Y total return vs ACB's -92.0%
  • Lower volatility, beta 0.98, Low D/E 0.1%, current ratio 19.59x
  • Beta 0.98, current ratio 19.59x
Best for: income & stability and long-term compounding
ACB
Aurora Cannabis Inc.
The Growth Play

ACB is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
  • 11.2% margin vs CGC's -111.0%
  • 5.2% ROA vs CGC's -29.5%, ROIC 0.7% vs -10.2%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthCRON logoCRON64.4% revenue growth vs CGC's -9.5%
ValueCRON logoCRONLower P/E (34.3x vs 164.2x)
Quality / MarginsACB logoACB11.2% margin vs CGC's -111.0%
Stability / SafetyCRON logoCRONBeta 0.98 vs CGC's 1.90, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)CRON logoCRON+38.9% vs ACB's -25.3%
Efficiency (ROA)ACB logoACB5.2% ROA vs CGC's -29.5%, ROIC 0.7% vs -10.2%

SNDL vs CGC vs CRON vs ACB — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SNDLSNDL Inc.
FY 2022
Cannabis
100.0%$62M
CGCCanopy Growth Corporation
FY 2024
Canadian Cannabis Net Revenue
57.9%$156M
Storz And Bickel
27.3%$73M
International And Other Revenue
14.8%$40M
Other Revenue
0.0%$0
CRONCronos Group Inc.
FY 2025
Cannabis Flower
74.0%$108M
Cannabis Extracts
25.7%$38M
Product and Service, Other
0.3%$411,000
ACBAurora Cannabis Inc.

Segment breakdown not available.

SNDL vs CGC vs CRON vs ACB — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCRONLAGGINGCGC

Income & Cash Flow (Last 12 Months)

ACB leads this category, winning 3 of 6 comparable metrics.

SNDL is the larger business by revenue, generating $937M annually — 4.8x CRON's $193M. ACB is the more profitable business, keeping 11.2% of every revenue dollar as net income compared to CGC's -111.0%. On growth, CRON holds the edge at +2.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSNDL logoSNDLSNDL Inc.CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
RevenueTrailing 12 months$937M$294M$193M$361M
EBITDAEarnings before interest/tax$49M-$32M-$810,000$71M
Net IncomeAfter-tax profit-$11M-$327M-$9M$41M
Free Cash FlowCash after capex$53M-$86M-$163,766-$31M
Gross MarginGross profit ÷ Revenue+27.2%+22.8%+32.5%+62.7%
Operating MarginEBIT ÷ Revenue-0.8%-24.1%-1.5%+13.3%
Net MarginNet income ÷ Revenue-1.2%-111.0%-4.9%+11.2%
FCF MarginFCF ÷ Revenue+5.6%-29.3%-0.1%-8.7%
Rev. Growth (YoY)Latest quarter vs prior year-4.4%+20.9%+2.0%+6.8%
EPS Growth (YoY)Latest quarter vs prior year+32.8%+83.8%-100.0%-94.5%
ACB leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

SNDL leads this category, winning 2 of 4 comparable metrics.

On an enterprise value basis, ACB's 6.7x EV/EBITDA is more attractive than SNDL's 7.9x.

MetricSNDL logoSNDLSNDL Inc.CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
Market CapShares × price$376M$122M$981M$195M
Enterprise ValueMkt cap + debt − cash$301M$293M$190M$136M
Trailing P/EPrice ÷ TTM EPS-32.97x-0.28x164.21x
Forward P/EPrice ÷ next-FY EPS est.34.27x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple7.91x6.73x
Price / SalesMarket cap ÷ Revenue0.54x0.62x5.07x0.77x
Price / BookPrice ÷ Book value/share0.46x0.34x0.90x0.43x
Price / FCFMarket cap ÷ FCF8.83x
SNDL leads this category, winning 2 of 4 comparable metrics.

Profitability & Efficiency

ACB leads this category, winning 6 of 9 comparable metrics.

ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-43 for CGC. CRON carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs CGC's 5/9, reflecting strong financial health.

MetricSNDL logoSNDLSNDL Inc.CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
ROE (TTM)Return on equity-1.0%-43.1%-0.9%+7.2%
ROA (TTM)Return on assets-0.8%-29.5%-0.8%+5.2%
ROICReturn on invested capital-0.3%-10.2%-0.8%+0.7%
ROCEReturn on capital employed-0.4%-12.4%-0.3%+0.7%
Piotroski ScoreFundamental quality 0–96567
Debt / EquityFinancial leverage0.15x0.72x0.00x0.17x
Net DebtTotal debt minus cash-$102M$235M-$790M-$80M
Cash & Equiv.Liquid assets$273M$114M$792M$184M
Total DebtShort + long-term debt$170M$348M$2M$104M
Interest CoverageEBIT ÷ Interest expense-1.16x-7.79x6.27x
ACB leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CRON leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in CRON five years ago would be worth $3,342 today (with dividends reinvested), compared to $45 for CGC. Over the past 12 months, CRON leads with a +38.9% total return vs ACB's -25.3%. The 3-year compound annual growth rate (CAGR) favors CRON at 8.9% vs CGC's -55.9% — a key indicator of consistent wealth creation.

MetricSNDL logoSNDLSNDL Inc.CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
YTD ReturnYear-to-date-16.7%-5.0%-4.8%-21.0%
1-Year ReturnPast 12 months+11.5%-12.4%+38.9%-25.3%
3-Year ReturnCumulative with dividends-16.2%-91.4%+29.1%-47.2%
5-Year ReturnCumulative with dividends-81.1%-99.6%-66.6%-96.1%
10-Year ReturnCumulative with dividends-98.3%-94.3%+1457.6%-92.0%
CAGR (3Y)Annualised 3-year return-5.7%-55.9%+8.9%-19.2%
CRON leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

CRON leads this category, winning 2 of 2 comparable metrics.

CRON is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than CGC's 1.90 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRON currently trades 74.9% from its 52-week high vs CGC's 47.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSNDL logoSNDLSNDL Inc.CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
Beta (5Y)Sensitivity to S&P 5001.18x1.90x0.98x1.81x
52-Week HighHighest price in past year$2.89$2.38$3.43$6.67
52-Week LowLowest price in past year$1.15$0.84$1.84$3.07
% of 52W HighCurrent price vs 52-week peak+50.2%+47.5%+74.9%+51.4%
RSI (14)Momentum oscillator 0–10049.752.949.352.2
Avg Volume (50D)Average daily shares traded1.9M10.4M1.4M979K
CRON leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: SNDL as "Hold", CGC as "Hold", CRON as "Hold", ACB as "Hold". Consensus price targets imply 1180.5% upside for CGC (target: $14) vs -10.5% for CRON (target: $2).

MetricSNDL logoSNDLSNDL Inc.CGC logoCGCCanopy Growth Cor…CRON logoCRONCronos Group Inc.ACB logoACBAurora Cannabis I…
Analyst RatingConsensus buy/hold/sellHoldHoldHoldHold
Price TargetConsensus 12-month target$3.95$14.47$2.30$5.92
# AnalystsCovering analysts6261514
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+3.0%0.0%+1.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

ACB leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CRON leads in 2 (Total Returns, Risk & Volatility).

Best OverallCronos Group Inc. (CRON)Leads 2 of 6 categories
Loading custom metrics...

SNDL vs CGC vs CRON vs ACB: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is SNDL or CGC or CRON or ACB a better buy right now?

For growth investors, Cronos Group Inc.

(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). Aurora Cannabis Inc. (ACB) offers the better valuation at 164. 2x trailing P/E, making it the more compelling value choice. Analysts rate SNDL Inc. (SNDL) a "Hold" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — SNDL or CGC or CRON or ACB?

Over the past 5 years, Cronos Group Inc.

(CRON) delivered a total return of -66. 6%, compared to -99. 6% for Canopy Growth Corporation (CGC). Over 10 years, the gap is even starker: CRON returned +1458% versus SNDL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — SNDL or CGC or CRON or ACB?

By beta (market sensitivity over 5 years), Cronos Group Inc.

(CRON) is the lower-risk stock at 0. 98β versus Canopy Growth Corporation's 1. 90β — meaning CGC is approximately 93% more volatile than CRON relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.

04

Which is growing faster — SNDL or CGC or CRON or ACB?

By revenue growth (latest reported year), Cronos Group Inc.

(CRON) is pulling ahead at 64. 4% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -100. 0% for Cronos Group Inc.. Over a 3-year CAGR, CRON leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — SNDL or CGC or CRON or ACB?

Aurora Cannabis Inc.

(ACB) is the more profitable company, earning 0. 5% net margin versus -222. 4% for Canopy Growth Corporation — meaning it keeps 0. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACB leads at 1. 4% versus -43. 5% for CGC. At the gross margin level — before operating expenses — ACB leads at 54. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is SNDL or CGC or CRON or ACB more undervalued right now?

Analyst consensus price targets imply the most upside for CGC: 1180.

5% to $14. 47.

07

Which pays a better dividend — SNDL or CGC or CRON or ACB?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is SNDL or CGC or CRON or ACB better for a retirement portfolio?

For long-horizon retirement investors, Cronos Group Inc.

(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +1458% 10Y return). Canopy Growth Corporation (CGC) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1458%, CGC: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between SNDL and CGC and CRON and ACB?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SNDL is a small-cap quality compounder stock; CGC is a small-cap quality compounder stock; CRON is a small-cap high-growth stock; ACB is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SNDL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Stocks Like

CGC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 13%
Run This Screen
Stocks Like

CRON

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 100%
  • Gross Margin > 19%
Run This Screen
Stocks Like

ACB

Steady Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 6%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SNDL and CGC and CRON and ACB on the metrics below

Revenue Growth>
%
(SNDL: -4.4% · CGC: 20.9%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.